Cannaray is a leading European cannabis company stratifying medical THC and a CBD lifestyle brand.
We are on a mission to heal ourselves from within and help pave the way for our friends and families. We believe in creating products good enough for ourselves as well as treating our customers like family.
Our assets include Therismos Limited, a UK company with the licences to import, handle, and distribute controlled drugs in the UK and all of Europe, as well as an exclusive alliance with Newey, the largest potted plant grower in the UK with over 4 million square feet of greenhouse space. We are building a pharmaceutical research lab to conduct research on novel delivery forms as well as product development. The company is also in the process of applying for a cannabis growing licence.
The business strategy is to become the European market leader first by entering into Germany, the largest medical cannabis market to date, followed by Poland and the UK. Finally, we will launch a lifestyle CBD brand backed by science and research.
Cannaray’s team brings a new level of professionalism to the cannabis industry with expertise covering IPOs, building companies through consolidation, life sciences, media, consumer and retail, all complementary backgrounds to create tangible shareholder value in medical cannabis and retail CBD.
Expertise in starting and building businesses. Scott has played a key role as an executive in building five companies or divisions of larger companies from concept to high value including trade sales and IPO. Scott has built a company from two patents to a NASDAQ listing (ticker: XBIO) and has also built a dialysis clinic chain from scratch to the UK’s second-largest private provider of dialysis services. He has assisted in building National Medical Care’s fledging international business from $15M to $350M in revenues. Scott also built a healthcare corporate finance practice from scratch to 35 professionals globally.
Highly experienced, successful chairman in NED roles and former CEO positions, across various food manufacturing sectors, in blue-chip corporates and private equity-backed businesses, with particular skills in deal-making, turnarounds and transformation, and building great teams with specific focus on executional excellence, meeting or exceeding the needs of all stakeholders, particularly value creation for shareholders. Chairman/CEO of companies with transaction values of $1.5B.
Experienced CFO, qualified Chartered Accountant and board-level director with a demonstrated history of developing and growing service businesses leading to improved shareholder value. Numerous M&A activities including the successful exit of a private equity-owned business. Developed significant improvements in management reporting, controls and strong financial reporting acting as a business partner for the development of the organisations. Lead several refinancings with strong banking relationship experience.
Investor and entrepreneur with experience in institutional investment and trading, international real estate investment, and private market investment. Joshua worked for Highbridge Capital Management for over a decade in London and New York and established the European trading desk for the StatArb team in London. He started angel investing in 2010 and cannabis has been his investment focus since early 2017 in both the public and private markets.
Serial entrepreneur with brand, design, and advertising expertise. Leah has experience starting, funding and exiting businesses as well as taking on roles as creative director, UX/UI designer for web/mobile/app programs, product management, production, traditional advertising, editorial art direction, press, media, and social media content curation. Leah was a founding member of Gilt Groupe where she was responsible for the vision, design, brand, voice, customer journey, and internal ad agency for all business verticals and projects. Leah has managed customer bases of over two million and was responsible for the daily operation for every customer touchpoint.
Strengthening Cannaray’s offering is a world-class Board of Directors covering industry-specific expertise in listing and running public companies, life sciences, financial, legal, media and the cannabis industry.
The SAB is comprised of key opinion leaders covering the four approved indications to treat with medical cannabis in the UK (chemotherapy-induced nausea and vomiting, epilepsy, multiple sclerosis, chronic pain).
Cannaray is pleased to announce the pivotal acquisition of Therismos Limited, a UK company with the licences to import, handle, and distribute controlled drugs in the UK as well as across Europe, Norway, Switzerland, and Iceland. The closing of this deal is fundamental to Cannaray’s strategy to become the leading European medical cannabis company and makes Cannaray one of the largest revenue-generating European cannabis companies. The company plans to raise additional capital in order to fund medical cannabis production and open up markets beyond the UK, beginning with Germany and Poland this year.